Three Dose Regimen of Tranexamic Acid in Cardiac Surgery
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has
seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in
cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The
current study includes patients receiving valvular replacement and coronary artery bypass
surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions
and clinical outcomes are recorded.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital